Marc Dionne
- Formation
- à venir
Aucune offre active
Autres opportunités de carrière
- Axe principal
- Santé des populations et environnementale
- Adresse
- 2875, boulevard Laurier, Édifice Delta II, 6e étage, bureau 600
Québec (Québec)
CANADA G1V 2M2 - Téléphone
- +1 418-666-7000, poste 240
- Télécopieur
- +1 418-654-2776
- Courriel
- marc.dionne@inspq.qc.ca
Projet(s) de recherche reconnu(s) par l'Université Laval
Autre(s) projet(s) de recherche actif(s)
Aucun projet de recherche à afficher
Publications récentes (voir toutes les publications de ce chercheur)
Quach C, McArthur M, McGeer A, Li L, Simor A, Dionne M, Levesque E, Tremblay L. Risk of infection following a visit to the emergency department: a cohort study. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne,
2012. Epub
Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, Schuind A, Descamps D. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: Results from a randomized study. Human vaccines,
2011. 7: 1374-86
Gilca V, De Serres G, Hamelin ME, Boivin G, Ouakki M, Boulianne N, Sauvageau C, Dionne M, Gilca R, Skowronski D. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine,
2011. 30: 35-41
Halperin SA, McNeil S, Langley J, Blatter M, Dionne M, Embree J, Johnson R, Latiolais T, Meekison W, Noya F, Senders S, Zickler P, Johnson DR. Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose. Vaccine,
2011. 29: 8459-65
Scheifele DW, Ward BJ, Dionne M, Vanderkooi O, Langley JM, Dobson S, Li Y, Law B, Halperin SA, for the Public Health Agency of Canada/Canadian Institutes of Health. Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children. The Pediatric infectious disease journal,
2011. 30: 402-7
Gilca R, De Serres G, Boulianne N, Ouhoummane N, Papenburg J, Douville-Fradet M, Fortin E, Dionne M, Boivin G, Skowronski DM. Risk factors for hospitalization and severe outcomes of 2009 pandemic H1N1 influenza in Quebec, Canada. Influenza and other respiratory viruses,
2011. 5: 247-55
Krajden M, Cook D, Yu A, Chow R, Mei W, McNeil S, Money D, Dionne M, Karunakaran KP, Palefsky JM, Dobson S, Ogilvie G, Petric M. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clinical and vaccine immunology : CVI,
2011. 18: 418-23
Gilca V, Dionne M, Boulianne N, Murphy D, De Serres G. Long-term immunogenicity of two pediatric doses of combined hepatitis A and B or monovalent hepatitis B vaccine in 8 to 10-year-old children and the effect of a challenge dose given seven years later. The Pediatric infectious disease journal,
2009. 28: 916-8
Gilca V, Sauvageau C, McNeil S, Gemmill IM, Dionne M, Dobson S, Ouakki M, Lavoie F, Duval B. Setting priorities for new vaccination programs by using public health officers and immunization managers opinions. Vaccine,
2008. 26: 4204-9
Guay M, Blackburn M, Pelletier A, Tremblay A, St-Hilaire C, Clément P, Clouâtre AM, Rousseau L, Landry M, St-Amand D, Dionne M. Étude sur les coûts et l'efficacité du programme de vaccination contre l'influenza au Québec Montréal, QC: Institut national de santé publique du Québec, 2007. 90 pages.
